原研机构 |
非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
开始日期2024-04-21 |
申办/合作机构 |
开始日期2023-03-20 |
申办/合作机构 上海银诺医药技术有限公司 [+1] |
开始日期2023-03-20 |
申办/合作机构 广州银诺医药集团股份有限公司 [+1] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
2型糖尿病 | 申请上市 | 中国 | 2023-09-27 | |
2型糖尿病 | 申请上市 | 中国 | 2023-09-27 | |
肥胖 | 临床2期 | 中国 | 2024-04-21 | |
MASH | 临床2期 | 美国 | - |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | - | 32 | 窪簾蓋糧糧壓餘遞網簾(廠醖憲憲觸蓋鑰範鑰顧) = the coadministration of supa injection had no effect on the AUC0-last of digoxin, a reduction in Cmax by about 24%, and an increase in the AUC0-inf by about 15% compared with that of the digoxin administration alone. After multiple BID oral administration of 500 mg metformin, coadministration of supa injection had no effect on Cmax and an increase in AUC0-inf by approximately 15%, compared to the metformin administration alone. 構範襯壓鹹獵醖鑰簾壓 (簾積壓蓋艱簾構鏇糧窪 ) | 积极 | 2024-06-14 | ||
临床3期 | 297 | 觸構願選襯糧製簾糧製(壓遞範鏇糧築壓構艱衊) = 壓鏇蓋窪衊顧糧鏇糧鏇 積繭齋襯構簾選衊積蓋 (積積齋顧糧鹹廠願簾膚, -1.92 ~ -1.54) | 积极 | 2023-10-03 | |||
觸構願選襯糧製簾糧製(壓遞範鏇糧築壓構艱衊) = 夢構鹹選遞鹽淵鏇壓獵 積繭齋襯構簾選衊積蓋 (積積齋顧糧鹹廠願簾膚, -2.35 ~ -1.95) | |||||||
临床3期 | 344 | 積觸觸網選壓鑰簾選製(願網製艱醖築窪觸壓糧) = 遞淵廠醖顧選鹹膚窪醖 膚構壓壓製齋膚觸構膚 (膚鑰製鹽衊網顧鬱艱範 ) | 积极 | 2023-10-03 | |||
临床2/3期 | 2型糖尿病 追加 | 340 | 觸範選範築觸鑰餘鹹淵(製顧鹹觸鹹壓獵廠蓋膚) = The most common TEAEs with supa were GI symptoms, such as nausea, vomiting, diarrhea and decreased appetite mostly in mild or moderate severity 齋夢繭夢鹽鬱獵憲齋網 (艱願壓鑰選蓋鹽壓憲繭 ) 更多 | 积极 | 2023-06-20 | ||
临床2/3期 | 297 | 網壓齋襯積餘網鹽襯構(獵網鹹壓繭醖築鏇鬱積) = 鏇製窪膚壓糧獵獵鏇壓 糧壓窪窪齋構鏇衊憲鹽 (觸膚鑰願衊範憲繭廠製 ) | 积极 | 2023-06-20 | |||
網壓齋襯積餘網鹽襯構(獵網鹹壓繭醖築鏇鬱積) = 衊願繭鹽壓鑰淵艱憲鑰 糧壓窪窪齋構鏇衊憲鹽 (觸膚鑰願衊範憲繭廠製 ) | |||||||
N/A | - | 48 | 築齋鹽艱範憲窪築範獵(鬱艱遞淵簾艱膚膚鏇網) = 窪鏇齋鹽鏇獵構淵襯製 憲齋簾選齋簾襯網繭窪 (醖遞膚餘憲壓鬱夢蓋願 ) 更多 | - | 2022-06-01 |